Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis.

作者: Farhad Alexander-Sefre , Helga B. Salvesen , Andy Ryan , Naveena Singh , Lars A. Akslen

DOI: 10.1016/S0090-8258(03)00505-5

关键词: PathologyBiologyMyometriumProspective cohort studyEndometrial cancerMicrodissectionClinical significanceInfiltration (medical)EndometriumOncogene

摘要: Abstract Introduction Overall nearly 20% of endometrial cancer (EC) patients die the disease and over half these had initially presented with clinical stage I disease. There is a strong correlation between mortality depth myometrial invasion. Current assessment invasion relies on light microscopy. Tumor cells can evade detection by microscopy if they are vastly outnumbered cells. Molecular techniques have great potential in such isolated Objective The objective was to develop model for application molecular advance risk status EC. Methods study sample included 21 ECs documented K-ras mutation from two series 96 106 United Kingdom Norway, respectively. using heteroduplex mobility analysis amplified created restriction site, followed sequencing identify specific base substitution at codon 12 13 oncogene. For each case mutation, modified mutant allele-specific amplification technique carried out tissue strips microdissected increasing depths myometrium underlying tumor. been previously examined histologically absence infiltrating tumor Presence mutations used within normal myometrium. Correlations submicroscopic cell infiltration clinicopathological factors were studied. Results Of cases 6 (28%) showed evidence beyond histological boundary. found be variable. staging tumors would changed 3 (14%) detected histologically. A borderline significant presence noted ( P = 0.053). recurrence rate survival without better than those with, although it did not reach statistical significance (recurrence 0.13, free 0.14, cause-specific 0.12, total 0.2). Conclusions feasible may add information conventional Further prospective studies required define this technology.

参考文章(48)
C. M. Johnston, T. S. Frank, R. F. Caduff, Mutations of the Ki-ras oncogene in carcinoma of the endometrium. American Journal of Pathology. ,vol. 146, pp. 182- 188 ,(1995)
Osamu Tanizawa, Naoki Terakawa, Alan O. Perantoni, Jerry M. Rice, Takayuki Enomoto, Masaki Inoue, K-ras Activation in Neoplasms of the Human Female Reproductive Tract Cancer Research. ,vol. 50, pp. 6139- 6145 ,(1990)
R Sedivy, B Wolf, M Kalipciyan, G G Steger, J Karner-Hanusch, R M Mader, Genetic analysis of multiple synchronous lesions of the colon adenoma-carcinoma sequence. British Journal of Cancer. ,vol. 82, pp. 1276- 1282 ,(2000) , 10.1054/BJOC.1999.1091
Osamu Tanizawa, Jerry M. Rice, Takayuki Enomoto, Masami Fujita, Taisei Nomura, Masaki Inoue, Ryuichi Nakajima, Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium Cancer Research. ,vol. 53, pp. 1883- 1888 ,(1993)
Gregory S. Buzard, Osamu Tanizawa, Alan O. Perantoni, Jerry M. Rice, Takayuki Enomoto, Hiroshi Miki, Masaki Inoue, K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Research. ,vol. 51, pp. 5308- 5314 ,(1991)
Peter Nollau, Christoph Wagener, on behalf of the IFCC Scientific Division, Committee on Molecular Biology Techniques, Methods for detection of point mutations: performance and quality assessment Clinical Chemistry. ,vol. 43, pp. 1114- 1128 ,(1997) , 10.1093/CLINCHEM/43.7.1114
Mirka W. Jones, Sophia Kounelis, Chia Hsu, Helen Papadaki, Anke Bakker, Patricia A. Swalsky, Sydney D. Finkelstein, Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. International Journal of Gynecological Pathology. ,vol. 16, pp. 354- 360 ,(1997) , 10.1097/00004347-199710000-00010
Helga B. Salvesen, Ingunn Stefansson, May Britt Kalvenes, Soma Das, Lars A. Akslen, Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. ,vol. 94, pp. 2185- 2191 ,(2002) , 10.1002/CNCR.10434